U.S. FDA Notifies Natco Pharma Unit in Hyderabad of Eight Observations

Natco Pharma, a pharmaceutical company, has been issued eight observations by the U.S. Food and Drug Administration (FDA) after an inspection of its pharmaceutical division in Kothur, Hyderabad, conducted between October 9 and October 18. Despite this development, Natco Pharma is resolute in its commitment to address and rectify these observations within the specified timeframe. The company is actively collaborating with the U.S. FDA to expedite the resolution of these matters. As a consequence of this news, the company's stock closed 1.27% lower, at ₹833.75 per share on the BSE.

Natco Pharma's operations primarily revolve around its formulations facility, where it manufactures a wide range of oral and solid dosages, encompassing dry powder, cytotoxic, noncytotoxic orals, and cytotoxic injectables.